Intech Investment Management LLC Has $7.78 Million Stake in Insmed, Inc. $INSM

Key Points

• Intech Investment Management LLC increased its holdings in Insmed, Inc. by 43.2%, now owning 101,979 shares worth approximately $7.78 million.
• Several institutional investors, including Mercer Global Advisors and Nuveen Asset Management, have also recently increased their stakes in Insmed, showcasing growing interest in the company.
• Despite a 17.3% earnings miss in its recent quarterly report, analysts maintain a positive outlook, with multiple firms raising their price targets on the stock, now averaging $139.86.

Intech Investment Management LLC raised its stake in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) by 43.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 101,979 shares of the biopharmaceutical company's stock after buying an additional 30,752 shares during the quarter. Intech Investment Management LLC owned about 0.06% of Insmed worth $7,780,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the company. Cullen Frost Bankers Inc. boosted its stake in Insmed by 164.9% during the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 221 shares during the last quarter. Elequin Capital LP acquired a new stake in Insmed in the fourth quarter worth $28,000. NBC Securities Inc. acquired a new position in shares of Insmed in the 1st quarter valued at $49,000. Versant Capital Management Inc increased its position in shares of Insmed by 546.3% in the 1st quarter. Versant Capital Management Inc now owns 698 shares of the biopharmaceutical company's stock valued at $53,000 after buying an additional 590 shares in the last quarter. Finally, Signaturefd LLC raised its stake in Insmed by 60.0% during the 1st quarter. Signaturefd LLC now owns 867 shares of the biopharmaceutical company's stock worth $66,000 after buying an additional 325 shares during the period.

Insider Activity

In related news, COO Roger Adsett sold 25,000 shares of the business's stock in a transaction on Tuesday, August 19th. The stock was sold at an average price of $127.58, for a total value of $3,189,500.00. Following the completion of the sale, the chief operating officer directly owned 105,637 shares in the company, valued at $13,477,168.46. The trade was a 19.14% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Sara Bonstein sold 58,400 shares of the company's stock in a transaction on Monday, July 21st. The shares were sold at an average price of $102.67, for a total value of $5,995,928.00. Following the completion of the transaction, the chief financial officer directly owned 73,505 shares in the company, valued at approximately $7,546,758.35. This represents a 44.27% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 378,382 shares of company stock valued at $40,169,038. Company insiders own 3.00% of the company's stock.

Insmed Stock Performance

INSM traded up $0.14 during trading hours on Friday, reaching $145.93. The company's stock had a trading volume of 1,926,423 shares, compared to its average volume of 2,126,632. Insmed, Inc. has a 52 week low of $60.40 and a 52 week high of $149.08. The company's 50-day moving average is $119.40 and its 200-day moving average is $92.09. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68. The firm has a market cap of $30.85 billion, a PE ratio of -25.56 and a beta of 0.97.

Insmed (NASDAQ:INSM - Get Free Report) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). The company had revenue of $107.42 million for the quarter, compared to analyst estimates of $104.06 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The business's quarterly revenue was up 18.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.94) EPS. Insmed has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Insmed, Inc. will post -4.56 EPS for the current year.

Analyst Upgrades and Downgrades

INSM has been the topic of several recent analyst reports. Stifel Nicolaus lifted their price objective on Insmed from $121.00 to $145.00 and gave the company a "buy" rating in a report on Thursday, August 14th. Jefferies Financial Group raised their target price on shares of Insmed from $129.00 to $148.00 and gave the stock a "buy" rating in a report on Wednesday, August 13th. Guggenheim lifted their price target on shares of Insmed from $125.00 to $172.00 and gave the company a "buy" rating in a research note on Monday, September 8th. The Goldman Sachs Group boosted their target price on Insmed from $114.00 to $142.00 and gave the company a "buy" rating in a research note on Wednesday, August 13th. Finally, William Blair assumed coverage on Insmed in a report on Wednesday, August 20th. They set an "outperform" rating on the stock. Sixteen analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $139.86.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.